Fox Chase Cancer Center

University of California

Georgetown University

Institute for Cancer Research

Samsung Electronics Co., Ltd.

Louis M Weiner

James David Marks

Gregory P Adams

Eva M Horak

Erica A Golemis

Ilya G Serebriiskii

Igor Astsaturov

Shangzi Wang

Hossein Borghaei

Ji Min Lee

Kyung Ah Kim

Jill P Smith

Bo Gyou Kim

Robert R Clarke

Sandra Jablonski

Andrew Godwin

Sandeep Nadella

Vladimir Ratushny

Rochelle E Nasto

Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.

Treating cancer with a CCK receptor inhibitor and an immune checkpoint inhibitor

Compositions and methods for the treatment and diagnosis of cancer are disclosed.

EGFR/NEDD9/TGF-&#x3b2; interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders

The invention relates to methods of inhibiting the growth or proliferation of a cell, the method comprising reducing the expression or activity of at least one gene in the cell selected from the group consisting of BLOC1S1, CDC2L1, CNOT1, DDX54, EIF3I, FANCG, FBP1, IER2, KIF1A, LCK, NR2F1, PNRC1, POLR2A, POLR2B, POLR2C, PRPF6, PSMB4, PSMC5, PSMD1, RPS2, SCNN1A, SF3A3, TAF2, TOB1 and TSC22D4.

Methods of inhibiting proliferation of estrogen-independent cancer cells

A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.

Combination therapy for the treatment of cancer using an anti-C-met antibody

Antibodies that specifically bind to an epitope on the extracellular domain of TEM7R are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided. The antibodies may be used in methods for treating tumors and for inhibiting angiogenesis in tumors.

Antibodies to tumor endothelial marker 7R

Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.

Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer

Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.

Bispecific single chain Fv antibody molecules and methods of use therof

Anti-EGFR family member antibodies and bispecific antibodies comprising one or more anti-EGFR family member antibodies are disclosed. These antibodies can be used to advantage to specifically target forms of cancer associated with the overexpression of members of the EGFR protein family.

Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof

Bispecific single chain Fv antibody molecules and methods of use thereof

Growing community of inventors

Philadelphia, PA, United States of America

Louis M Weiner